

Marina DÃ-az-BeyÃ;

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2214586/publications.pdf>

Version: 2024-02-01

41
papers

1,097
citations

567281

15
h-index

454955

30
g-index

43
all docs

43
docs citations

43
times ranked

2061
citing authors

#	ARTICLE	IF	CITATIONS
1	Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. <i>Blood</i> , 2013, 121, 2734-2738.	1.4	246
2	The Incidence of Venous Occlusive Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Has Diminished and the Outcome Improved over the Last Decade. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1713-1720.	2.0	170
3	Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. <i>Annals of Hematology</i> , 2010, 89, 1233-1237.	1.8	134
4	CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies. <i>Molecular Therapy</i> , 2021, 29, 636-644.	8.2	80
5	The lincRNA <i>HOTAIRM1</i> , located in the <i>HOXA</i> genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature. <i>Oncotarget</i> , 2015, 6, 31613-31627.	1.8	78
6	Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance. <i>PLoS ONE</i> , 2018, 13, e0199531.	2.5	60
7	The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status. <i>Blood</i> , 2010, 116, 6147-6148.	1.4	41
8	A phase II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia. <i>Annals of Hematology</i> , 2018, 97, 763-772.	1.8	39
9	Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia. <i>Haematologica</i> , 2020, 105, e294-e297.	3.5	29
10	Acute myeloid leukemia with <i>NPM1</i> mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease. <i>British Journal of Haematology</i> , 2020, 191, 52-61.	2.5	28
11	European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. <i>Blood Advances</i> , 2022, 6, 1193-1206.	5.2	26
12	Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1. <i>Annals of Hematology</i> , 2014, 93, 1695-1703.	1.8	25
13	MiR-SNPs as Markers of Toxicity and Clinical Outcome in Hodgkin Lymphoma Patients. <i>PLoS ONE</i> , 2013, 8, e64716.	2.5	21
14	A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2394-2404.	1.3	16
15	Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34); <i>DEK</i> <i>NUP214</i> shows a favourable outcome when performed in first complete remission. <i>British Journal of Haematology</i> , 2020, 189, 920-925.	2.5	16
16	Adverse prognostic impact of complex karyotype (≥ 3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). <i>Leukemia Research</i> , 2021, 109, 106612.	0.8	11
17	Factors associated with the clinical outcome of patients with relapsed/refractory CD19 ⁺ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy. , 2021, 9, e003644.		11
18	Characteristics and Outcome of Early T Cell Precursor ALL (ETP-ALL) Patients Treated with High-Risk Spanish Pethema Protocols. <i>Blood</i> , 2018, 132, 1553-1553.	1.4	6

#	ARTICLE	IF	CITATIONS
19	Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease. American Journal of Hematology, 2022, 97, 731-739.	4.1	6
20	Early T-cell precursor lymphoblastic leukaemia: response to FLAG-IDA and high-dose cytarabine with sorafenib after initial refractoriness. British Journal of Haematology, 2019, 185, 755-757.	2.5	5
21	Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation. Leukemia Research, 2011, 35, 1276-1278.	0.8	4
22	Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma. Cancer Cell International, 2015, 15, 122.	4.1	4
23	Piwirna-651 Expression Influences Treatment Response and Impacts Survival in Classical Hodgkin Lymphoma Patients through Regulation of ABCC5. Blood, 2014, 124, 134-134.	1.4	4
24	Refining the Diagnosis and Prognostic Categorization of Acute Myeloid Leukemia Patients with an Integrated Use of Cytogenetic and Molecular Studies. Acta Haematologica, 2013, 129, 65-71.	1.4	3
25	Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials. Hematological Oncology, 2021, 39, 529-538.	1.7	3
26	Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) in First Complete Remission Is Superior Compared to Chemotherapy/Autologous HSCT in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia Lacking Mutations in NPM1, FLT3-ITD, and CEBPA: A Joint Study of AMLSG, Cetlam and Acute Leukemia Working Party of EBMT. Blood, 2014, 124, 324-324.	1.4	2
27	Genomic Data Improves Prognostic Stratification in Adult T-Cell Acute Lymphoblastic Leukemia Patients Enrolled in Measurable Residual Disease-Oriented Trials. Blood, 2021, 138, 3486-3486.	1.4	2
28	Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival. Leukemia and Lymphoma, 2018, 59, 2383-2393.	1.3	1
29	A Revised International Prognostic Scoring System of 3.5 Points Stratifies Patients with Myelodysplastic Syndromes into 2 Risk Categories. Blood, 2020, 136, 9-10.	1.4	1
30	Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1 Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Measurable Residual Disease (MRD): Results of a Preemptive Intervention Policy (CETLAM-2012 Protocol). Blood, 2018, 132, 1385-1385.	1.4	1
31	Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan. Bone Marrow Transplantation, 0, , .	2.4	1
32	Clinic and therapeutic potential of non-coding RNAs in cancer. Translational Cancer Research, 2021, 10, 0-0.	1.0	0
33	Treatment With G-CSF Reduces Acute Myeloid Leukemia (AML) Blasts Viability In Presence Of Bone Marrow Stroma. Blood, 2013, 122, 1422-1422.	1.4	0
34	The LincRNA HOTAIRM1, Located in the HOXA genomic Region, impacts Prognosis in Acute Myeloid Leukemia and Is Associated with a Distinctive microRNA Signature. Blood, 2014, 124, 1003-1003.	1.4	0
35	Outcomes after Plerixafor Plus FLAG-IDA (PLERIFLAG) Versus FLAG-IDA +/- Gentuzumab for Adult Patients with First Relapsed/Refractory AML: A Propensity Score Analysis from the Pethema Registry. Blood, 2019, 134, 1321-1321.	1.4	0
36	Design and In Vitro Evaluation of a CAR-T Prototype (ARI-0003) Targeting CD123 for Acute Myeloid Leukemia. Blood, 2021, 138, 4799-4799.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Myeloproliferative/Myelodysplastic Neoplasms Presenting All Diagnostic Criteria of Chronic Myelomonocytic Leukemia but with Absolute Peripheral Blood Monocytosis 0.5-1Å— 109/L Should be Classified As CMML. <i>Blood</i> , 2020, 136, 10-11.	1.4	0
38	Prospective Population-Based Analysis of Characteristics and Therapy Options in AML: The Case of Catalonia (PERIS Project). <i>Blood</i> , 2020, 136, 32-33.	1.4	0
39	Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012). <i>Blood</i> , 2020, 136, 31-32.	1.4	0
40	Risk-Adapted Intensive Chemotherapy for Primary ACUTE Myeloid Leukemia during the Last 25 YEARS: Increase in Complete Remission RATE, Hematopoietic Cell Transplantation Access and Decrease in Relapse Incidence Have LED to Improved Survival. <i>Blood</i> , 2020, 136, 13-14.	1.4	0
41	Emergence of <i>NPM1</i> Wild-Type Myeloid Neoplasms after Chemotherapy for Acute Leukemia with <i>NPM1</i> Mutation: Proposed Mechanisms of Clonal Evolution. <i>Blood</i> , 2020, 136, 39-40.	1.4	0